加入收藏|
400-655-1678
网站公告: 欢迎关注我们的最新动态!因为专业,所以卓越!
>> 返回 您当前所在位置:首页 > 品牌展示 > 正文

Open Biosystems

更新时间:2013-01-07 08:52:55点击次数:1686次字号:T|T
Open Biosystems成立于2001年,是一家非常具有发展前景的美国生物公司。其2002年与IMAGE (Integrated Molecular Analysis of Genomes and their Expression)联盟达成协议,面向全球销售IMAGE联盟所属的基因资源。该公司可以提供的产品线主要有三个方面: 基因克隆: 可以提供IMAGE联盟、MGC、Incyte、CGAP等组织的所有基因资源,数量达千万个,包括人和小鼠的全长cDNA克隆、肿瘤基因组的EST、正常...
相关介绍

    Open Biosystems成立于2001年,是一家非常具有发展前景的美国生物公司。其2002年与IMAGE (Integrated Molecular Analysis of Genomes and their Expression)联盟达成协议,面向全球销售IMAGE联盟所属的基因资源。该公司可以提供的产品线主要有三个方面:
    基因克隆:
    可以提供IMAGE联盟、MGC、Incyte、CGAP等组织的所有基因资源,数量达千万个,包括人和小鼠的全长cDNA克隆、肿瘤基因组的EST、正常及肿瘤组织的全长cDNA克隆、大鼠和人的BAC克隆等。客户可以单独购买其中的个别克隆,也可以购买某一类型的克隆(BioTrack计划,如MAPkinase信号途径、糖酵解途径、细胞凋亡、调节和代谢等生理途径的cDNA克隆组合)或者整个文库。可以这么说,Openbiosystems可以为您提供任何您所需要的基因克隆。

    RNAi干扰文库:

    包括美国冷泉港(CSHL)实验室Dr.Greg Hannon提供的基于改造的逆转录病毒载体的shRNA文库(Expression Arrest shRNA Library)和有哈佛大学(Harvard) Steve Elledge提供的基于改造的假病毒载体的shRNA文库(TRC)。构建的shRNA文库为大规模筛选基因功能提供了基础。

    抗体服务:

    根据客户的需求定制高质量的抗体
     
    We are part of Thermo Fisher Scientific, the world leader in serving science. Thermo Fisher Scientific enables customers to make the world healthier, cleaner and safer by providing analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery and diagnostics. With annual sales of more than $9 billion, Thermo Fisher Scientific has 30,000 employees and serves more than 350,000 customers in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies as well as environmental, industrial quality and process control settings.

    Open Biosystems was founded in 2001 by a team of researchers who believe deeply in the power of science to improve our lives, and yours, too. This conviction, coupled with our strong desire to help our customers succeed, motivates our employees and gives us our unrelenting focus on developing and delivering the best life sciences tools, support and services to our customers available in the industry today.

    Our business model, based on a collaborative spirit and focused on the value of product delivery, is inspired by the success of the open source movement in software. Open source has, over the span of just a few years, radically empowered small organizations and individuals by giving them the tools only big companies could previously afford. We aim to speed the progress of research by letting people use our technology in a manner that’s substantially more flexible than that of other tools providers.

    Open Biosystems offers products that span Genomics, RNAi and Antibodies. Building on the rapid sharing model that is at the core of the Human Genome Project, Open Biosystems collaborates with some of the most innovative life science investigators working today. We partner with them to bring to market new products—they have often pioneered the new resources in their own lab, and we prepare it for widespread use and then provide access to the research community.

    Delivery of genetic content is our most recent technological breakthrough. Recently, we brought to market the Tranz-vector system, the safest human-based lentiviral delivery technology. Further supplementing our already strong line of RNA interference (RNAi) and complementary DNA (cDNA) products, this technology provides investigators with superior delivery capabilities for high-quality cellular screening. The combination or our unique Tranz-vector system and whole genome RNAi & cDNA content enables our customers to perform drug target validation on a large scale.

    With our genomics resources, Open Biosystems provides the content investigators utilize to unlock the functions of human genes and their relationships to normal & disease development. We offer the most complete gene library in the industry. This novel library consists of several full length cDNA and open reading frame collections. Most prominently among these is the Mammalian Gene Collection (MGC), the industry’s gold standard gene catalog.

    The discovery of RNA interference has revolutionized the way investigators approach the studies of gene expression, regulation and interactions, particularly as it relates to drug development. Our collaboration with Drs. Greg Hannon (CSHL) and Steve Elledge (Harvard) has led the way in the evolution of the short hairpin RNA (shRNA) technologies to provide the life science community with whole genome resources for human, mouse and rat with a multitude of technology and delivery advantages.


如有任何问题,请联系客服!